Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A non-randomized prospective clinical trial comparing the non-inferiority of Salpingectomy to Salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [sorock]

Ovarian

A Randomized Phase III Study of Systemic Therapy with or without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial

M23-384: A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Lung

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors

Miscellaneous

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared with Placebo Both with Background First-Line Chemotherapy in Adult Participants with Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic

A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study

Leukemia

A Randomized Phase III Trial Comparing Radiation Therapy (RT) Plus Carboplatin/Paclitaxel vs. RT Plus Cetuximab for Patients with Locoregionally Advanced Head and Neck Cancer Who Have a Contraindication to Cisplatin (CONCISE)

Head/Neck

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy

Multiple Cancer Types